drugset / Trial / NCT06267794

Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.

NCT06267794

Phase 2 Completed 180 enrolled Jorge L Poo
RandomizedParallel-groupTriple-blindTreatment

Summary

This will be a multicenter, double-blind clinical trial to evaluate the safety and efficacy of two doses of prolonged release pirfenidone, compared against placebo plus conventional therapy in patients with compensated liver cirrhosis. The study will be conducted in compliance with International Standard good clinical practices (GCPs) and the Declaration of Helsinki. The protocol is approved by a local Institutional Review Board and registered in clinical trials.gov.

Timeline

Start
2015-06-26
Primary completion
2021-12-30
Completion
2023-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirfenidone Small molecule 1200 mg
Subject Pirfenidone Small molecule 1800 mg